
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Biotechnology · market cap $2.3B · as of 2026-06-30
Research and calibrated estimates, not financial advice — verify before acting.
| Asset | Phase | Indication |
|---|---|---|
| IMVAMUNE | Phase 2 | Smallpox |
| MVA-BN | Phase 2 | Monkeypox (Mpox) |
| MVA BN® | Phase 3 | 18-42 Year Old Healthy Vaccinia-naïve Subjects |
| CHIKV VLP vaccine booster | Phase 3 | Chikungunya Virus Infection |
| BN-Brachyury plus radiation | Phase 2 | Chordoma |
| IMVAMUNE® | Phase 3 | Smallpox |
| CHIKV VLP/unadjuvanted | Phase 2 | Chikungunya Virus Infection |
| CHIKV VLP vaccine | Phase 3 | Chikungunya Virus |
| PROSTVAC-V | Phase 3 | Prostate Cancer Metastatic |
| CHIKV VLP/adjuvant | Phase 3 | Chikungunya Virus |
| CV301 | Phase 2 | Bladder Cancer |
| MVA-BN-WEV | Phase 2 | Encephalitis |
| MVA-mBN85B | Phase 2 | Measles |
| PXVX0200 | Phase 3 | Cholera |
| MVA-nef | Phase 2 | HIV Infection |
| MVA-BN-RSV | Phase 2 | Respiratory Syncytial Virus Infections |
| IMVAMUNE (MVA-BN) | Phase 2 | Smallpox |
| MVA-mBN294B | Phase 2 | RSV Infection |
| ABNCoV2 | Phase 3 | COVID-19 Disease |
| MVA-mBN32 | Phase 2 | HIV Infections |
Daily closes through 2025-12-12. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
See ProApproval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.